Bacterial production of ciprofloxacin and potential usage as a radiotracer.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
05
2023
accepted:
29
08
2023
medline:
13
11
2023
pubmed:
9
11
2023
entrez:
9
11
2023
Statut:
epublish
Résumé
Infectious diseases caused by bacteria that have become resistant to antibiotics have increased in prevalence, necessitating new methods for their diagnosis and treatment. The aim of this study was to compare the efficacy of synthetic ciprofloxacin to that of organic ciprofloxacin produced by cave microorganisms, as well as to evaluate the feasibility of using organic ciprofloxacin radiolabeled with technetium-99m as an imaging agent. Organic ciprofloxacin produced by cave bacteria isolated from sediment taken from the dark zone of Antalya's "Yark Sinkhole," (Turkey's 14th deepest cave), was purified using high-performance liquid chromatography. Purified organic ciprofloxacin and standard ciprofloxacin were radiolabeled with technetium-99m (99mTc), and their uptake by pathogenic microorganisms as well as potential as an imaging agent were examined. According to thin-layer radiochromatography, radiolabeling efficiencies were 98.99 ± 0.34 (n = 7) and 91.25 ± 1.84 (n = 7) for radiolabeled organic ciprofloxacin and standard ciprofloxacin respectively. The binding efficiency of radiolabeled organic ciprofloxacin at the 240th minute was higher compared with radiolabeled standard ciprofloxacin, especially with P.aeruginosa, MRSA, VRE and E.coli. The results demonstrate that radiolabeling with 99mTc does not alter the biological behavior of organic ciprofloxacin, and radiolabeled organic ciprofloxacin has potential as an imaging agent for the detection of bacterial infection. The original value of the study is the monitoring of the antibiofilm effects of untouched cave-derived organic antibiotics by radiolabeling with a radionuclide.
Identifiants
pubmed: 37943851
doi: 10.1371/journal.pone.0291342
pii: PONE-D-23-13182
pmc: PMC10635501
doi:
Substances chimiques
Ciprofloxacin
5E8K9I0O4U
Technetium
7440-26-8
Radiopharmaceuticals
0
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0291342Informations de copyright
Copyright: © 2023 Karatay et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Biotechnol. 2013 Jun 20;166(1-2):34-41
pubmed: 23651950
Front Public Health. 2022 Dec 21;10:1025633
pubmed: 36620240
Metallomics. 2011 Oct;3(10):1041-8
pubmed: 21833405
PLoS One. 2012;7(4):e34953
pubmed: 22509370
Sci Rep. 2021 Jan 12;11(1):514
pubmed: 33436712
J Clin Med. 2019 Feb 06;8(2):
pubmed: 30736324
Heliyon. 2021 Feb 20;7(2):e06310
pubmed: 33718642
Mol Biol Rep. 2018 Oct;45(5):1457-1468
pubmed: 29974398
J Anaesthesiol Clin Pharmacol. 2017 Jul-Sep;33(3):300-305
pubmed: 29109626
Perspect Medicin Chem. 2014 Aug 28;6:25-64
pubmed: 25232278
J Nucl Med. 2003 Jun;44(6):920-6
pubmed: 12791820
Microb Ecol. 2022 Oct;84(3):676-687
pubmed: 34693460
Clin Transl Imaging. 2016;4:229-252
pubmed: 27512687
Front Microbiol. 2019 Mar 22;10:387
pubmed: 30967844
AAPS J. 2004;6(2):1-6
pubmed: 18465265
Microb Ecol. 2009 Apr;57(3):484-93
pubmed: 18677528
Eur J Nucl Med. 2000 Mar;27(3):292-301
pubmed: 10774881
Microb Biotechnol. 2014 May;7(3):209-20
pubmed: 24661414
Antibiotics (Basel). 2021 Oct 05;10(10):
pubmed: 34680793
JAMA. 2016 Sep 20;316(11):1193-1204
pubmed: 27654605
Antimicrob Agents Chemother. 2008 Jul;52(7):2691-2
pubmed: 18474577